Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 22

Results For "US"

7469 News Found

Lilly plans to more than double US manufacturing investment since 2020 exceeding $50 billion
News | March 03, 2025

Lilly plans to more than double US manufacturing investment since 2020 exceeding $50 billion

Company expects to begin building four more domestic manufacturing sites this year and add 13,000 high-wage manufacturing and construction jobs in America


Lupin secures a place in S&P Global Sustainability Yearbook 2025
Sustainability | February 28, 2025

Lupin secures a place in S&P Global Sustainability Yearbook 2025

Yearbook members are selected basis their S&P Global 2024 Corporate Sustainability Assessment score


Zydus Lifesciences to launch protection against new strain of influenza virus
News | February 27, 2025

Zydus Lifesciences to launch protection against new strain of influenza virus

VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives


Glenmark Pharmaceuticals USA launches Epinephrine Injection USP
News | February 27, 2025

Glenmark Pharmaceuticals USA launches Epinephrine Injection USP

This launch of Epinephrine Injection multiple-dose Vial is eligible for 180 days of CGT exclusivity under section 505(j)(5)(B)(v) of the FD&C Act.


USFDA issues Form 483 with 3 observations to Gland Pharma's Sterile APIs unit
Drug Approval | February 27, 2025

USFDA issues Form 483 with 3 observations to Gland Pharma's Sterile APIs unit

The observations issued are neither repeated observations nor related to data integrity


Caplin Steriles receives USFDA final approval for ANDA Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution
Drug Approval | February 27, 2025

Caplin Steriles receives USFDA final approval for ANDA Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution

Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure


Venus Remedies secures in-licensing rights from Infex Therapeutics to develop and commercialize MET-X in India
News | February 27, 2025

Venus Remedies secures in-licensing rights from Infex Therapeutics to develop and commercialize MET-X in India

MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies


Biocon Biologics launches Yesintek Biosimilar to Stelara in US
News | February 25, 2025

Biocon Biologics launches Yesintek Biosimilar to Stelara in US

YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis